Stage II cervical cancer represents a critical point where the disease has begun to spread beyond the cervix, requiring carefully planned treatment to control the cancer and preserve quality of life. Understanding the available treatment options and emerging therapies can help patients and their families make informed decisions about care.

How Treatment Goals Shape the Care Pathway

When cervical cancer reaches stage II, the primary goals of treatment shift to controlling the spread of the disease, eliminating cancer cells both in the cervix and surrounding tissues, and maintaining the best possible quality of life during and after treatment. At this stage, the cancer has moved beyond the cervix itself but has not yet reached the pelvic walls or the lower portion of the vagina, creating a window of opportunity for aggressive treatment.^[1]

Treatment decisions depend heavily on the specific characteristics of each patient’s cancer. Stage II cervical cancer is divided into two substages that require different approaches. In stage IIA, the cancer has spread to the upper part of the vagina but not to the tissues surrounding the cervix. Stage IIA is further divided based on tumor size: stage IIA1 means the cancer measures 4 centimeters or less, while stage IIA2 indicates a tumor larger than 4 centimeters. Stage IIB represents a more advanced situation where the cancer has grown into the tissues next to the cervix, called the parametria, which are the supportive tissues that hold the cervix in place.^[2]

The treatment team considers multiple factors beyond just the stage when developing a care plan. A patient’s age, overall health, whether they wish to preserve fertility, and personal preferences all play important roles. Medical organizations like the British Gynaecological Cancer Society and the International Federation of Gynecology and Obstetrics provide detailed guidelines to help doctors determine the most appropriate treatment approach for each individual situation.^[1]

Modern treatment for stage II cervical cancer typically involves combinations of therapies rather than a single approach. Standard treatments approved by medical societies have been used for many years with well-understood results, while research continues into new drugs and methods that might improve outcomes. Clinical trials offer some patients access to these promising experimental treatments that are not yet widely available.^[13]

Standard Treatment Approaches for Stage II Disease

The foundation of treatment for most patients with stage II cervical cancer is a combination of chemotherapy and radiation therapy given at the same time, known as chemoradiation or concurrent chemoradiotherapy. This approach has become the standard of care because chemotherapy helps make radiation therapy more effective at destroying cancer cells. The chemotherapy drugs work to sensitize the cancer cells, making them more vulnerable to the damaging effects of radiation.^[5]

The chemotherapy component typically involves drugs from the platinum family, most commonly cisplatin. When cisplatin is used, it is usually given once per week throughout the radiation therapy schedule. In some cases, doctors may use a combination of cisplatin plus another drug called 5-fluorouracil (also known as 5-FU or Adrucil). When this combination is used, it is typically administered every four weeks during the radiation treatment period.^[12]

The radiation therapy portion consists of two different types delivered in sequence. External beam radiation therapy involves a machine that aims high-energy x-rays at the pelvis from outside the body. This treatment is given five days per week for approximately five to six weeks. Each daily session lasts only a few minutes, though patients must lie still in a specific position to ensure the radiation reaches the correct area.^[1]

Following external radiation, most patients receive brachytherapy, which is a form of internal radiation therapy. During a procedure in the operating room or treatment suite, doctors place small devices containing radioactive material directly into the cervix and vagina. This allows a very high dose of radiation to be delivered right where the cancer is located while limiting exposure to nearby healthy organs like the bladder and rectum. The radioactive sources may be left in place for a period ranging from a few minutes to several days, depending on the specific type of brachytherapy used.^[5]

In some situations, additional radiation may be given as a “boost” to the pelvic lymph nodes if there is concern that cancer cells may have spread to these small filtering structures. The lymph nodes are part of the body’s immune system and are located along the blood vessels in the pelvis.^[1]

Surgery plays a more limited role in stage II cervical cancer compared to earlier stages, but it may be appropriate for carefully selected patients. For some women with stage IIA1 disease (where the tumor is 4 centimeters or smaller and limited to the upper vagina), a radical hysterectomy might be offered. This operation removes the uterus, cervix, the upper portion of the vagina, and the parametrial tissues. The surgeon also removes the pelvic lymph nodes to check for cancer spread. However, this surgical approach is typically only considered for younger women who are strong candidates for surgery and only when the tumor meets specific size and location criteria.^[5]

For patients with stage IIB disease, where the cancer has spread into the parametrial tissues, surgery is rarely the primary treatment. However, some women may undergo a surgical procedure to remove the pelvic lymph nodes before receiving radiation therapy or chemoradiation. This lymph node dissection helps doctors determine whether cancer has spread to the nodes, which can influence decisions about the extent and intensity of radiation treatment needed.^[12]

In rare cases where patients cannot tolerate chemotherapy due to other health conditions, radiation therapy may be given alone without concurrent chemotherapy. While this approach is less effective than combined chemoradiation, it remains an option for patients whose overall health makes chemotherapy too risky.^[5]

The typical duration of treatment for stage II cervical cancer extends over several months. The active treatment period with external radiation and chemotherapy lasts about six to seven weeks, followed by the brachytherapy procedures. After completing treatment, patients enter a recovery period where the body heals from the effects of therapy. Follow-up appointments continue for years afterward to monitor for any signs of cancer recurrence.^[12]

Managing Side Effects of Standard Treatment

Both chemotherapy and radiation therapy can cause side effects that affect patients during and after treatment. Understanding these potential effects helps patients prepare and know when to seek help from their medical team. During external radiation therapy, many women experience fatigue that gradually increases over the weeks of treatment. The skin in the treatment area may become red, irritated, or sensitive, similar to a sunburn. Radiation to the pelvis commonly causes digestive symptoms including diarrhea, nausea, and cramping because the intestines pass through the radiation field.^[17]

Chemotherapy side effects depend on the specific drugs used. Cisplatin, the most common chemotherapy for cervical cancer, can cause nausea and vomiting, though modern anti-nausea medications help control these symptoms for most patients. Cisplatin may affect kidney function, so regular blood tests monitor kidney health throughout treatment. Some patients experience numbness or tingling in their hands and feet, a condition called peripheral neuropathy, which may improve after treatment ends. Hair thinning can occur with some chemotherapy regimens, though complete hair loss is less common than with chemotherapy used for other cancers.^[5]

The bladder and rectum, which sit close to the cervix, can be irritated by radiation. This may cause an increased need to urinate, discomfort with urination, or rectal irritation and occasional bleeding. These symptoms often improve after treatment ends, though some women experience long-term changes in bowel or bladder function that require ongoing management.

Radiation to the pelvis affects the ovaries, leading to menopause in women who have not yet gone through this transition naturally. The sudden onset of menopause can cause hot flashes, mood changes, and vaginal dryness. Hormone replacement therapy may be discussed with patients to help manage these symptoms. Radiation can also cause narrowing and loss of elasticity in the vagina, which may affect sexual function. Doctors often recommend the use of vaginal dilators and moisturizers to help maintain vaginal health after treatment.^[17]

Promising Therapies Being Studied in Clinical Trials

While chemoradiation remains the standard treatment for stage II cervical cancer, researchers continue to investigate new approaches that might improve cure rates and reduce side effects. Clinical trials represent the pathway through which these experimental treatments are carefully tested before becoming widely available. Understanding the different phases of clinical trials helps patients appreciate what participation involves.

Phase I trials are the earliest studies in humans, focusing primarily on safety. These trials determine the appropriate dose of a new drug and identify what side effects occur. Phase I trials typically enroll small numbers of patients who have advanced cancer that has not responded to standard treatments. Phase II trials expand testing to more patients to learn whether the new treatment shows evidence of effectiveness against specific types of cancer. These studies continue to monitor safety while gathering preliminary data on whether tumors shrink or disease progression slows. Phase III trials are large studies that compare a new treatment directly to the current standard treatment. These trials provide the strongest evidence about whether a new approach is better than, equivalent to, or less effective than existing options.^[13]

Immunotherapy Approaches

One of the most exciting areas of research for cervical cancer involves harnessing the body’s own immune system to fight cancer. Most cervical cancers are caused by human papillomavirus (HPV), and these virus-associated cancers may be particularly vulnerable to immune-based treatments. Immunotherapy drugs work by removing the brakes that cancer cells place on the immune system, allowing immune cells to recognize and attack the tumor.^[13]

The immunotherapy drug pembrolizumab (also known by the brand name Keytruda) has shown promise in clinical trials for cervical cancer. Pembrolizumab belongs to a class of drugs called checkpoint inhibitors that target a protein called PD-1 on immune cells. In studies of advanced cervical cancer, pembrolizumab has been tested both alone and in combination with chemotherapy. While originally studied in more advanced stages of disease, researchers are investigating whether adding immunotherapy to standard chemoradiation for stage II disease might improve outcomes.^[13]

The mechanism by which pembrolizumab works involves blocking the interaction between PD-1 on immune T-cells and PD-L1 on cancer cells. Normally, when PD-1 and PD-L1 connect, they send a signal telling the immune cell to stand down and not attack. Cancer cells exploit this system by producing PD-L1, essentially hiding from the immune system. By blocking this interaction with pembrolizumab, the immune cells become active again and can target the cancer.

Targeted Therapy with Bevacizumab

Bevacizumab (brand name Avastin) represents another category of newer cancer drugs called targeted therapies. Rather than attacking all rapidly dividing cells like traditional chemotherapy, targeted therapies aim at specific molecules that cancer cells need to grow and spread. Bevacizumab targets a protein called vascular endothelial growth factor (VEGF) that tumors use to build new blood vessels, a process called angiogenesis.^[13]

Tumors cannot grow beyond a tiny size without developing their own blood supply. Cancer cells release VEGF to stimulate the formation of new blood vessels that bring oxygen and nutrients to the tumor. Bevacizumab blocks VEGF, essentially starving the tumor by preventing it from building the blood vessel network it needs. Clinical trials have tested bevacizumab in combination with chemotherapy and, more recently, with chemotherapy plus pembrolizumab for advanced cervical cancer. Some studies are exploring whether adding bevacizumab to treatment might benefit patients with locally advanced disease including stage II tumors.

Investigating Alternative Chemotherapy Regimens

While cisplatin-based chemotherapy has been the backbone of concurrent treatment with radiation for years, researchers continue to evaluate whether other chemotherapy drugs or combinations might be equally effective with fewer side effects. Carboplatin, a drug similar to cisplatin but with a different side effect profile, is being studied as an alternative. Carboplatin may cause less kidney damage and nausea than cisplatin, potentially making it easier for some patients to tolerate.^[13]

Clinical trials are comparing weekly cisplatin to carboplatin given in various schedules during radiation therapy. Some studies investigate combination regimens using two chemotherapy drugs rather than one. The goal of this research is to find the optimal balance between effectiveness and tolerability, recognizing that treatment must be potent enough to cure the cancer while remaining manageable for patients to complete the full course.

Exploring Neoadjuvant Chemotherapy Followed by Surgery

Some research has investigated a different treatment sequence called neoadjuvant chemotherapy, where patients receive chemotherapy before any other treatment. The idea behind this approach is to shrink the tumor with chemotherapy first, potentially making it easier to remove with surgery or making radiation therapy more effective. For stage II cervical cancer, some trials have tested giving several cycles of chemotherapy followed by radical hysterectomy.^[16]

However, recent large clinical trials have provided important information about this approach. When researchers combined data from studies comparing neoadjuvant chemotherapy plus surgery to standard chemoradiation, they found that the neoadjuvant approach was associated with worse outcomes. Specifically, for stage IIB cervical cancer, disease-free survival was significantly shorter for patients who received neoadjuvant chemotherapy and surgery compared to those treated with standard chemoradiation. Overall survival was similar between the two approaches, but the higher rate of cancer recurrence with the neoadjuvant approach led most experts to continue recommending chemoradiation as the preferred treatment for stage II disease.^[16]

Research Into Optimizing Radiation Techniques

Beyond new drugs, researchers are also working to improve radiation therapy techniques. Intensity-modulated radiation therapy (IMRT) is a sophisticated form of external beam radiation that shapes the radiation beams to match the tumor’s contours more precisely. This technology aims to deliver higher doses to the cancer while reducing exposure to nearby healthy organs. Studies are evaluating whether IMRT can reduce side effects compared to conventional radiation while maintaining effectiveness against the cancer.

Similarly, advances in brachytherapy techniques continue to evolve. Image-guided brachytherapy uses MRI or CT scans to help doctors place the radioactive sources in the optimal position and calculate the precise dose distribution. This personalized approach to brachytherapy is being studied to determine whether it improves cure rates and reduces complications compared to standard techniques.

Most Common Treatment Methods

• Chemoradiation (Concurrent Chemotherapy and Radiation Therapy)
  • Combines external beam radiation therapy given five days per week for approximately five to six weeks with weekly chemotherapy, most commonly cisplatin
  • Chemotherapy makes radiation more effective at destroying cancer cells
  • Followed by internal radiation therapy (brachytherapy) where radioactive sources are placed directly in the cervix
  • Represents the primary treatment approach for most patients with stage II cervical cancer
  • May include additional radiation boost to pelvic lymph nodes if cancer spread is suspected
• Surgery
  • Radical hysterectomy with removal of pelvic lymph nodes may be offered for selected patients with stage IIA1 disease (tumors 4 cm or smaller)
  • Removes the uterus, cervix, upper vagina, parametrial tissues, and lymph nodes
  • Typically followed by radiation therapy or chemoradiation if high-risk features are found
  • Lymph node dissection alone may be performed before chemoradiation in stage IIB disease to assess lymph node involvement
  • Not a standard primary treatment for most stage II patients
• Immunotherapy
  • Pembrolizumab is a checkpoint inhibitor drug being studied in clinical trials for cervical cancer
  • Works by blocking the PD-1/PD-L1 interaction, allowing immune cells to recognize and attack cancer
  • Being tested alone and in combination with chemotherapy and targeted therapy
  • Originally studied in advanced disease but under investigation for earlier stages
• Targeted Therapy
  • Bevacizumab targets VEGF to prevent tumors from building new blood vessels
  • Studied in combination with chemotherapy and immunotherapy in clinical trials
  • Aims to starve tumors by cutting off their blood supply